Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSeretide evohaler

    Seretide Evohaler

    Jump to

    • Mylan's Asthma drug launch in UK negative for Cipla: BoAML

      Brokerage Bank of America Merrill Lynch (BoAML) feels the launch of asthma drug by Mylan in the UK is negative for Cipla because earlier the drug maker was expected to be the first company to launch this drug. Shares of Cipla fell nearly 2 percent in early trade Tuesday.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347